• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

2.430 -0.080 (-3.19%)
Delayed Quote Updated: 12:14 PM EDT, Oct 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 262,442
Open 2.520
Bid (Size) 2.430 (2,600)
Ask (Size) 2.440 (4,200)
Prev. Close 2.510
Today's Range 2.425 - 2.520
52wk Range 2.435 - 7.950
Shares Outstanding 68,196,526
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product
October 20, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
October 15, 2026
From Niagen Bioscience, Inc.
Via Business Wire

Performance

52-Week Range 69.4% below 52-week high
2.430
2.4452W Low 7.9552W High
1 Week 6.5% below 1-week high
2.441W Low 2.601W High

Niagen Bioscience, Inc. - Common Stock (NAGE) traded between $2.44 and $7.95 over the past 52 weeks and last traded at $2.43, 69.4% below its 52-week high. Over the past week it ranged between $2.44 and $2.60.

Past 12 Months
-4.0%
-20.1%
-30.4%
-48.7%
-61.1%
-66.3%
1W -$0.10
1M -$0.61
3M -$1.06
6M -$2.31
YTD -$3.82
1Y -$4.78

NAGE was -66.3% over the past year, -48.7% over six months, -61.1% year to date, -4.0% in the last week.

12 Months vs Market
NAGE
-66.3%
DIA
+12.5%
SPY
+15.1%
QQQ
+18.7%
IWM
+11.4%

Over the past 12 months NAGE returned -66.3% versus DIA (Dow) +12.5%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +18.7% and IWM (Russell 2000) +11.4%.

Volume & Liquidity 0.47× 3-mo avg
Today 262,442 3-mo avg 554.9K
1W
510.5K
1M
557.6K
3M
554.9K
6M
703.0K
YTD
854.7K
1Y
861.1K

NAGE most recently traded 262,442 shares against a 3-month average daily volume of 554.9K.

More News

Read More
News headline image
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
October 08, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
October 06, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
October 01, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
September 30, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
September 21, 2026
From Niagen Bioscience, Inc.
Via Business Wire
News headline image
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
September 17, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
September 10, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at Longevity Investors Conference
September 02, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
August 26, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
August 20, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
August 12, 2026
From Niagen Bioscience, Inc.
Via Business Wire
News headline image
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
August 06, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
August 04, 2026
From Niagen Bioscience, Inc.
Via Business Wire
News headline image
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
August 03, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
July 28, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
July 27, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
July 21, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
July 16, 2026
From Niagen Bioscience, Inc.
Via Business Wire
News headline image
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
July 13, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
July 09, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
July 08, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
June 03, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
June 02, 2026
From Niagen Bioscience, Inc
Via Business Wire

Frequently Asked Questions

Is Niagen Bioscience, Inc. - Common Stock publicly traded?
Yes, Niagen Bioscience, Inc. - Common Stock is publicly traded.
What exchange does Niagen Bioscience, Inc. - Common Stock trade on?
Niagen Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Niagen Bioscience, Inc. - Common Stock?
The ticker symbol for Niagen Bioscience, Inc. - Common Stock is NAGE on the Nasdaq Stock Market
What is the current price of Niagen Bioscience, Inc. - Common Stock?
The current price of Niagen Bioscience, Inc. - Common Stock is 2.430
When was Niagen Bioscience, Inc. - Common Stock last traded?
The last trade of Niagen Bioscience, Inc. - Common Stock was at 10/21/26 12:14 PM ET
What is the market capitalization of Niagen Bioscience, Inc. - Common Stock?
The market capitalization of Niagen Bioscience, Inc. - Common Stock is 165.72M
How many shares of Niagen Bioscience, Inc. - Common Stock are outstanding?
Niagen Bioscience, Inc. - Common Stock has 166M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap